The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis

References

• Multiple Sclerosis Trust. Prevalence and incidence of multiple sclerosis [Internet]. Hertfordshire: Multiple Sclerosis Trust [cited 2016 Aug 23]. Available from: https://www.mstrust.org.uk/a-z/prevalence-and-incidence-multiple-sclerosis
   Google Scholar
• Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9:520–532.
   PubMed Web of Science ®Google Scholar
• Evans C, Beland SG, Kulaga S, et al. Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology. 2013;40(3):195–210.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013;40:307–323.
   PubMed Web of Science ®Google Scholar
• Amato MP, Zipoli V, Portaccio E. Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies. J Neurol Sci. 2006;245:41–46.
   PubMed Web of Science ®Google Scholar
• Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler (Houndmills, Basingstoke, England). 2000;6:91–98.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74:2004–2015.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler (Houndmills, Basingstoke, England). 2012;18:7–15.
   PubMed Web of Science ®Google Scholar
• Trojano M, Paolicelli D, Tortorella C, et al. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? Neurol Clin. 2011;29:309–321.
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Doxani C, Mprotsis T, et al. Network analysis of randomized controlled trials in multiple sclerosis. Clin Therapeut. 2012;34:857–869.e9.
   PubMed Web of Science ®Google Scholar
• Product Monograph: Glatect, Glatiramer acetate injection, 20 mg/1 mL, Pre-filled Syringes for Subcutaneous Injection [Internet]. Montréal, QC: Pharmascience Inc [cited 2018 July 23]. Available from: https://pdf.hres.ca/dpd_pm/00037836.PDF
   Google Scholar
• Product Monograph: Pglegridy, peginterferon beta-1a, Liquid for injection 125 µg [Internet]. Mississauga, ON: Biogen Canada Inc. [cited 2018 July 23]. Available from: https://www.biogen.ca/content/dam/corporate/en_CA/pdfs/products/PLEGRIDY/PLEGRIDY_PM_E.pdf
   Google Scholar
• Multiple Sclerosis Society of Canada. Health Canada approves Plegridy for the management of relapsing–remitting MS [Internet]. Ontario: MS Society of Canada [cited 2018 July 23]. Available from: https://mssociety.ca/research-news/article/health-canada-approves-plegridy-for-the-management-of-relapsing-remitting-ms
   Google Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Derfuss T, Ontaneda D, Nicholas J, et al. Relapse rates in patients with multiple sclerosis treated with fingolimod: subgroup analyses of pooled data from three phase 3 trials. Mult Scler Relat Disord. 2016;8:124–130.
   PubMed Web of Science ®Google Scholar
• Hutchinson M. Predicting and preventing the future: actively managing multiple sclerosis. Pract Neurol. 2009;9:133–143.
   PubMedGoogle Scholar
• Bergvall N, Makin C, Lahoz R, et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PloS One. 2014;9:e88472.
   PubMed Web of Science ®Google Scholar
• He A, Spelman T, Jokubaitis V, et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol. 2015;72(4):405–413.
   PubMed Web of Science ®Google Scholar
• Braune S, Lang M, Bergmann A. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis. J Neurol. 2015;263(2):327–333.
   PubMed Web of Science ®Google Scholar
• AAN Position. Availability of disease modifying therapies (DMT) for treatment of relapsing forms of multiple sclerosis [Internet]. Minneapolis, MN: American Academy of Neurology [cited 2016 May 20]. Available from: https://www.aan.com/AAN-Resources/Details/contact-aan/
   Google Scholar
• Multiple Sclerosis Society of Canada. Disease-modifying therapies [Internet]. Ontario: MS Society of Canada [cited 2016 Nov 09]. Available from: https://mssociety.ca/managing-ms/treatments/medications/disease-modifying-therapies-dmts
   Google Scholar
• Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing–remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011;10(6):520–529.
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58(6):840–846.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–1452.
   PubMed Web of Science ®Google Scholar
• Ontario Ministry of Health and Long-Term Care. Schedule of Benefits for Physician Services Under the Health Insurance Act [Internet]. Ontario: Health and Long-Term Care [cited 2018 May 16]. Available from: http://www.health.gov.on.ca/en/pro/programs/ohip/sob/physserv/sob_master20160401.pdf
   Google Scholar
• Ontario Ministry of Health and Long-Term Care. Schedule of Benefits for Laboratory Services [Internet]. Ontario: Health and Long-Term Care [cited 2018 May 16]. Available from: http://www.health.gov.on.ca/en/pro/programs/ohip/sob/lab/lab_mn2018.pdf
   Google Scholar
• Ontario Ministry of Health and Long-Term Care. Ontario Case Costing Initiative (OCCI) [Internet]. Ontario: Health and Long-Term Care [cited 2018 May 16]. Available from: https://www.ontario.ca/data/ontario-case-costing-initiative-occi
   Google Scholar
• Ariste R, Béjaoui A. Estimating nursing wage bill in Canada and breaking down the growth rate: 2000 to 2010. Healthc Policy. 2015;10(4):48–60.
   PubMedGoogle Scholar
• Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005;11(2):232–239.
   PubMed Web of Science ®Google Scholar
• Gajofatto A, Bacchetti P, Grimes B, et al. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis. Mult Scler. 2009;15(1):50–58.
   PubMed Web of Science ®Google Scholar
• Carra A, Onaha P, Luetic G, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina. Eur J Neurol. 2008;15(4):386–393.
   PubMed Web of Science ®Google Scholar
• Grand’Maison F, Yeung M, Morrow SA, et al. Sequencing of disease-modifying therapies for relapsing–remitting multiple sclerosis: a theoretical approach to optimizing treatment. Curr Med Res Opin. 2018;34(8):1419–30.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Thomas K. Treatment optimization in multiple sclerosis: how do we apply emerging evidence? Expert Rev Clin Immunol. 2017;13(6):509–511.
   PubMed Web of Science ®Google Scholar
• Freedman MS, Selchen D, Prat A, Giacomini PS. Managing multiple sclerosis: treatment initiation, modification, and sequencing. Can J Neurol Sci. 2018;45(5):489–503.
   PubMed Web of Science ®Google Scholar
• Alsop J, Medin J, Cornelissen C, et al. Two studies in one: a propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL. PLoS One. 2017;12(5):e0173353.
   PubMed Web of Science ®Google Scholar
• He A, Spelman T, Jokubaitis V, et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol. 2015;72(4):405–13.
   PubMed Web of Science ®Google Scholar
• Lapierre Y, O’Connor P, Devonshire V, et al. High persistence with fingolimod in Canadian routine clinical practice. Mult Scler. 2015;21(11_suppl):76–653.
   PubMed Web of Science ®Google Scholar
• Bhan V, Lapierre Y, Devonshire V, et al. Fingolimod in routine clinical practice: Canadian experience. Mult Scler. 2016;22(3_suppl):88–399.
   Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Therapeut Clin Pharmacol. 2012;19(1):e11–25.
   PubMedGoogle Scholar
• Zecca C, Roth S, Findling O, et al. Real-life long-term effectiveness of fingolimod in a Swiss relapsing–remitting multiple sclerosis cohort (P6.356). Neurology. 2017;88(16 Suppl):P6.356.
   Google Scholar
• Chitnis T, Silva D, Ghezzi A, et al. Long-term efficacy of early fingolimod treatment in young adult patients with relapsing multiple sclerosis (P6.385). Neurology. 2018;90(15 Suppl):P6.385.
   Google Scholar
• Ziemssen T, Albrecht H, Haas J, et al. 5 years effectiveness of fingolimod in daily clinical practice: results of the non-interventional study PANGAEA documenting RRMS patients treated with fingolimod in Germany (P6.345). Neurology. 2017;88(16 Suppl):P6.345.
   Google Scholar
• Druart C, El Sankari S, van Pesch V. Long-term safety and real-world effectiveness of fingolimod in relapsing multiple sclerosis. Patient Relat Outcome Meas. 2018;9:1–10.
   PubMed Web of Science ®Google Scholar
• Agashivala N, Kim E. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis. Clin Therapeut. 2012;34(7):1583–1590.
   PubMed Web of Science ®Google Scholar
• Product Monograph: Gilenya, Fingolimod (as fingolimod hydrochloride), Oral capsules, 0.5 mg fingolimod (as fingolimod hydrochloride). Quebec: Novartis Pharmaceuticals Canada Inc. [cited 2018 Nov 7]. Available from: https://www.novartis.ca/sites/www.novartis.ca/files/gilenya_patient_e.pdf
   Google Scholar
• Sanchez-de la Rosa R, Sabater E, Casado MA. Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing–remitting multiple sclerosis in Spain. Health Econ Rev. 2013;3:13.
   PubMedGoogle Scholar
• Capkun G, Dahlke F, Lahoz R, et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord. 2015;4(6):546–554.
   PubMed Web of Science ®Google Scholar
• MSIF. Atlas of MS 2013 [Internet]. London: MS International Federation [cited 2016 July 6]. Available from: http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf
   Google Scholar